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Abstract  
Carbon-11 labeled dihydrotetrabenazine (11C-DTBZ) binds to the vesicular monoamine 
transporter 2 and has been used to assess nigro-striatal integrity in animal models and 
patients with Parkinson’s disease. Here, we applied 11C-DTBZ positron emission 
tomography (PET) to obtain longitudinally in-vivo assessment of striatal dopaminergic 
loss in the classic unilateral and in a novel bilateral 6-hydroxydopamine (6-OHDA) 
lesion rat model. Forty-four Sprague–Dawley rats were divided into 3 sub-groups: 1. 6-
OHDA-induced unilateral lesion in the medial forebrain bundle, 2. Bilateral lesion by 
injection of 6-OHDA in the third ventricle, 3. Vehicle injection in either site. 11C-DTBZ 
PET studies were investigated in the same animals successively at baseline, 1, 3 and 6 
weeks after lesion using an anatomically standardized volumes-of-interest approach. 
Additionally, 12 rats had PET and Magnetic Resonance Imaging to construct a new 11C-
DTBZ PET template. Behavior was characterized by rotational, catalepsy and limb-use 
asymmetry tests and dopaminergic striatal denervation was validated post-mortem by 
immunostaining of the dopamine transporter (DAT). 11C-DTBZ PET showed a 
significant decrease of striatal binding (SB) values one week after the unilateral lesion. 
At this point, there was a 60% reduction in SB in the affected hemisphere compared 
with baseline values in 6-OHDA unilaterally lesioned animals. A 46% symmetric 
reduction over baseline SB values was found in bilaterally lesioned rats at the first week 
after lesion. SB values remained constant in unilaterally lesioned rats whereas animals 
with bilateral lesions showed a modest (22%) increase in binding values at the 3rd and 
6th week post-lesion. The degree of striatal dopaminergic denervation was corroborated 
histologically by DAT immunostaining. Statistical analysis revealed a high correlation 
between 11C-DTBZ PET SB and striatal DAT immunostaining values (r = 0.95, 
p<0.001). The data presented here indicate that 11C-DTBZ PET may be used to ascertain 
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changes occurring in-vivo throughout the evolution of nigro-striatal dopaminergic 
neurodegeneration, mainly in the unilateral 6-OHDA lesion rat.  
 
Keywords: Parkinson’s disease, 6-hydroxydopamine, Positron emission tomography, 
[11C]-dihydrotetrabenazine (11C-DTBZ), Nigro-striatal depletion, Dopaminergic marker, 
Rat models. 
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Abbreviations 
3-D: Three-dimensional 
6-OHDA: 6-hydroxydopamine 
11C-CH3I: Carbon-11 labeled methyliodide 
11C-DTBZ: Carbon-11 labeled dihydrotetrabenazine  
ANOVA: Analysis of variance 
BR: Binding ratio 
DA: Dopamine  
DAT: Dopamine transporter 
DMSO: Dimethyl sulfoxide 
KOH: Potassium hydroxide 
MBq: Megabecquerel 
MFB: Medial forebrain bundle  
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI: Magnetic resonance imaging  
PD: Parkinson’s disease 
PET: Positron emission tomography  
RAMLA: Row action maximum likelihood algorithm 
SB: Striatal binding 
SNpc: Substantia nigra pars compacta 
SUV: Standardized uptake value 
VMAT2: Vesicular monoamine transporter 2 
VOI: Volume of interest 
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Introduction 
Parkinson’s disease (PD) is a progressive neurodegenerative disorder mainly 
characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta 
(SNpc) and dopamine (DA) striatal depletion. Positron emission tomography (PET) 
imaging can be used for in-vivo assessment of the dopaminergic nigro-striatal projection 
(Casteels et al., 2008). Dopamine undergoes pre-synaptic reuptake through the 
dopamine transporter (DAT) protein and is packaged into synaptic vesicles by the 
vesicular monoamine transporter 2 (VMAT2). In-vivo and histological measurement of 
these transporters is used as indicator of presynaptic nerve terminal integrity. Among the 
available radioligands, [11C]-dihydrotetrabenazine (11C-DTBZ) specifically binds to 
VMAT2 and is currently considered to be a highly sensitive marker of striatal pre-
synaptic dopaminergic activity in PD patients (Frey et al., 1996; de la Fuente-Fernández 
et al., 2011) and animal models (Strome et al., 2006; Sossi et al., 2007; Collantes et al., 
2008; Blesa et al., 2010) and several studies have shown an excellent correlation 
between 11C-DTBZ binding potential and histological nigro-striatal lesion (Strome et al., 
2006; Blesa et al., 2012; Brown et al., 2013). However, there is no study evaluating the 
longitudinal changes in 11C-DTBZ throughout the evolution of different lesion models. 
This is particularly interesting when considering the many changes that occur in the 
basal ganglia and elsewhere in the brain to compensate for initial dopaminergic 
depletion (Zigmond et al., 1989; Bezard et al., 2001, 2003; Pifl and Hornykiewicz, 
2006). Here, we report the modification of 11C-DTBZ PET in the unilateral 6-
hydroxydopamine (6-OHDA) model, and in a novel bilaterally lesioned rat model using 
intraventricular injection of 6-OHDA. 
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Material and methods 
Animals 
Fifty-six Sprague–Dawley rats (300 g; Harlan Ibérica, Barcelona, Spain) were 
used. All experimental procedures were carried out in accordance with the guidelines of 
the European Communities Council Directive (86/609/EEC) and the Spanish 
Government (Real Decreto 1201/2005) and were approved by the local Animal Ethics 
Committee (Universidad de Navarra Institutional Committee on Care and Use of 
Laboratory Animals).  
 
Experimental design  
In the unilateral model (Figure 1A), baseline PET studies were performed one 
week before surgery. Sham and 6-OHDA-lesioned animals underwent PET studies at 1, 
2, 3 and 6 weeks. The rotational screening by apomorphine administration was 
undertaken 3 weeks after the procedure. In the bilateral model (Figure 1B), PET studies 
were performed on sham and lesion animals 1, 3 and 6 weeks following the last 6-
OHDA injection (see below). Behavior was analyzed longitudinally by measuring 
forelimb use and catalepsy-grid tests. All animals were sacrificed one week after last 
PET image acquisition and immunohistochemistry studies were carried out at post-
mortem. Additionally, another 12 healthy rats underwent 11C-DTBZ PET scanning and 
Magnetic Resonance Imaging (MRI) for the construction of a new 11C-DTBZ PET 
template (Figure 2) to be used as reference for spatial normalization (Collantes et al., 
2009). These 12 baseline studies were also used as baseline reference values for the 
bilateral model. 
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Figure 1: Experimental protocol design for unilaterally (A) and bilaterally (B) 6-OHDA-
lesioned rat models of Parkinson's disease.  
(double column fitting image) 
 
Unilateral 6-OHDA lesion model 
Twenty-two rats received a dose of 1 µg/μl in 4 μl of 6-OHDA (Sigma-Aldrich, 
St. Louis, MO, USA) dissolved in saline with 0.02 % ascorbic acid to induce the 
unilateral lesion. Sham animals (n=4) received 0.02% ascorbic acid diluted in saline. All 
surgical procedures were performed under xylazine (0.5 ml/kg, i.p.; Xilagesic®; Calier 
Laboratories) and ketamine (1 ml/kg, i.p.; Imalgene 1000®, Merial Laboratories) 
anesthesia. All rats were placed in a stereotaxic head frame with the incisor bar 
positioned 4.5 mm below the interaural line. The coordinates of the stereotaxic injection 
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were: 4.0 mm anterior to the interaural line, +1.3 mm lateral to the midline, 8.4 mm 
ventral to the surface of the skull. The neurotoxic was injected at a rate of 0.5 μl/min by 
an infusion pump into the left medial forebrain bundle (MFB). 
 
Bilateral 6-OHDA lesion model 
Rats (n=18) were anesthetized with xylazine and ketamine and placed in a 
stereotaxic frame with the incisor bar positioned 0 mm below the interaural line. A 
guide cannula was positioned in the third ventricle (0.8 mm posterior to Bregma, 
midline and 6.5 mm ventral below the dura). Dental cement was applied to fix it and the 
frontal bone of the skull was used as an anchor point. Two weeks after surgery, 100 µg 
of 6-OHDA diluted in 0.02 % ascorbic acid in a volume of 4 μl of saline on seven 
consecutive days (n=13) or vehicle (n=5) were injected daily. All solutions were 
administered with an injector cannula at a rate of 1 μl/min using an infusion pump. Rats 
were awake and freely moving during the infusion period. 
 
Behavioral tests 
The apomorphine-induced (0.05 mg/kg s.c.; dissolved in saline) rotational 
behavior of the animals in the unilateral model was measured 3 weeks after lesion 
(Marin et al., 2009; Gago et al., 2013). The rats were placed in circular cages and 
tethered to an automated rotometer linked to a computer (Panlab-Harvard Apparatus, 
Spain) to record for 60 min the number of ipsilateral and contralateral rotations. Rats 
with contralateral rotations were considered valid and included in the study (one rat was 
excluded only). 
The evaluation of behavior in the bilateral model was performed by the 
catalepsy-grid (Rodríguez et al., 2001) and the forelimb use asymmetry (Sutton et al., 
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2013) tests, which were carried out a few minutes before and 2 hours after each 6-
OHDA or vehicle administration. After the last infusion the tests were performed once a 
day for 6 days and once per week up to 53 days. In the catalepsy-grid test, rats were 
gently placed on a wire grid at 45º above the surface. Catalepsy was considered to be 
present only when the animal remained completely immobile on the grid. We assessed 
the intensity of the cataleptic state by measuring the duration of immobile episodes 
during one minute, and the test was repeated four times, waiting 5 minutes between 
each observation period. The evaluation of the test was scored according with the 
following criteria: catalepsy present for 0 to 14 seconds, value of 0; from 15 to 29 
seconds, value of 1; from 30 to 59 seconds, value of 2; and more than 60 seconds, the 
maxim value of 3. In addition, animals were placed in a transparent cylinder for 5 min 
to quantify the independent use of the right or left forelimb for contacting the wall (the 
limb use asymmetry test). 
 
MicroPET scanning and MRI acquisition 
Monoaminergic PET imaging was performed at Clínica Universidad de Navarra 
in a dedicated small animal Philips MOSAIC tomograph (Cleveland, OH, USA). 
Details of the methodology and the acquisition system have been published previously 
(Huisman et al., 2007).  
All animals were anesthetized by isoflurane inhalation (2 % in 100 % oxygen 
gas) at the moment of the radiotracer injection and during PET image acquisition. 
Animals were placed on the PET scanner bed in prone position 15 min after radiotracer 
administration via the tail vein (37 ± 5 MBq in 0.2 ml of saline solution) to perform a 
static acquisition of 15 min. The radiotracer was synthesized as previously described 
(Quincoces et al., 2008), with minor modifications. Briefly, enantiomerically pure [11C]-
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(+)-α-dihydrotetrabenazine was obtained by O-methylation with [11C]CH3I of the 
desmethyl precursor (+)-9-O-desmethyl-α-dihydrotetrabenazine (ABX, Germany) in 
basic medium (KOH in DMSO). The final compound was purified by solid phase 
extraction, solvents evaporated under He flow and dry residue dissolved in saline.  
PET images were reconstructed using an iterative three-dimensional row action 
maximum likelihood algorithm (3-D RAMLA), with 2 iterations, on a 128×128×120 
matrix, where the voxel size equals 1×1×1 mm. Corrections for decay, random 
coincidences and scattering were applied. Images were normalized for the injected 
radiotracer dose and animal body weight, resulting in semi-quantitative images 
representing the standardized uptake value (SUV). 
MRI studies were performed at the Complutense University of Madrid and 
acquired in a BIOSPEC BMT 47/40 scanner (Bruker, Ettlingen, Germany) operating at 
4.7 Tesla. Rats were anesthetized with the same mixture of isoflurane and oxygen. The 
acquisition parameters and protocols have been described previously (Prieto et al., 
2011). 
 
Analysis of 11C-DTBZ PET images 
Spatial normalization procedure for all PET images required the creation of a 
11C-DTBZ PET template (Collantes et al., 2009). The entire creation process is shown 
in Figure 2. Briefly, each PET image of 12 healthy animals was registered to the 
corresponding MRI scan. Then, co-registered PET images were spatially normalized 
applying the transformation matrix from each MRI scan normalization process, using a 
T2-weighted MRI rat brain template (Schweinhardt et al., 2003) as first reference. A 
provisional PET template was constructed as a smoothed average of these pre-
normalized PET scans. Subsequently, all baseline PET studies underwent the process of 
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being normalized, averaged and smoothed in 3 iterations to finally obtain the 11C-DTBZ 
PET template. 
 
Figure 2: Step-wise process of the 11C-DTBZ PET template of the rat brain from MRI and 
PET images at baseline state.  
(double column fitting colored image) 
 
All PET images were normalized into the standard stereotaxic space (Paxinos 
and Watson, 2007) using the 11C-DTBZ PET template as reference with an automated 
algorithm based on mutual information using the PMOD fusion tool (version 3.2; 
PMOD Technologies Ltd., Adliswil, Switzerland). Final voxel dimensions were 
0.2x0.2x0.2 mm after the interpolation step of the spatial normalization process. 
Volume of interest (VOI) analysis was performed using PMOD software for the 
quantification of 11C-DTBZ PET images. A brain atlas (Frumberg et al., 2007) that 
contains the delineation of the brain (2.073 cm3) and striatum (0.044 cm3) was used as 
guidance to manually draw reduced striatum (0.022 cm3) and cerebellum (0.094cm3) 
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spatially-standardized VOIs, which were used to quantify the average SUV value of 
these regions in the images (Figure 3). 
 
Figure 3: Representative coronal (top) and axial (bottom) sections of spatially normalized 
MRI scan and 11C-DTBZ microPET images (at 1st week) of control, unilaterally- and 
bilaterally-lesioned animals. The figure shows the location of striatum (green) and 
cerebellum (light blue) anatomically-standardized volumes of interest (VOI) used to 
quantify standardized uptake value, brain outline (dark blue) and atlas-based striatum 
(red).  
(double column fitting colored image) 
 
Binding data were represented as striatal binding (SB) percentage measurements 
of a reference binding ratio (BR) value. BR was expressed as the average of the left or 
right striatal SUV value divided by the average of the cerebellar SUV value minus one; 
BR = (SUVstriatum / SUVcerebellum) – 1. SB was estimated in the unilateral model as a 
percentage of the BR value in the lesioned side with respect to the intact BR value (2.10 
13 
 
 
 
± 0.41); SB unilateral model (%) = (BR lesioned side / BR intact side) x 100. In the bilateral model, 
SB measurements represented the percentage of the BR value of each side with respect 
to the average BR value from both striatum of healthy animals (2.36 ± 0.24); SB bilateral 
model (%) = (BR one side / BR baseline average) x 100.  
 
Immunohistochemistry and optical density analysis 
Immunohistochemistry studies were carried out for DAT detection using a 
standardized protocol in our laboratory (Gago et al., 2013). Coronal striatal sections (40 
µm-thick) were obtained using a cryostat (Microm, Walldorf, Germany), thaw-mounted 
on Superfrost® Plus slides (Thermo Scientific), and stored at -80ºC until used. The 
sections were thawed, dried at room temperature and fixed in acetone for 10 min at 4ºC. 
They were immersed in 0.3% hydrogen peroxide in PBS for 10 min to block the 
endogenous peroxidase. At this point, the sections were incubated with rabbit serum 
with 0.1% Triton X-100 for 30 min followed by overnight incubation at 4 °C with goat 
anti-DAT monoclonal antibody (1:500 in PBS; sc-1433, Santa Cruz Biotechnology, Inc., 
Dallas, TX). Sections were subsequently incubated with biotinylated rabbit anti-goat Ig-
G (Pierce, Thermo Fisher Scientific, Rockford, IL) for 30 min and an ABC Peroxidase 
staining kit (Vector Laboratories, Burlingame, CA) was used to carry out ABC staining. 
Finally, the sections were incubated with 3-3′-diaminobenzidine and 0.01% hydrogen 
peroxide for 10min. The slides were then washed with PBS, dehydrated in ascending 
alcohol concentrations, cleared in xylene and coverslipped in DPX mounting medium.  
DAT immunolabeling was estimated by using Image J software (NIH, Bethesda, 
MD, USA), and the optical density of the striatal region was measured.  
 
Statistical analysis  
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Statistical analyses were carried out using STATA software (StataCorp, Texas, 
USA). The difference in SB values between control groups (baseline and sham) and 
groups lesioned with the neurotoxin at different time points was set after testing the 
distribution of PET imaging data for normality (Shapiro-Wilk test) and homogeneity of 
variances (Levene's test). When normality could be assumed, data values were analyzed 
using two-way ANOVA (lesion group and repeated measures over time, factors); when 
not, a nonparametric Kruskal-Wallis equality-of-populations rank test was performed 
followed by Bonferroni correction and Mann-Whitney U-test (group factor). 
A one-way ANOVA followed by Bonferroni test was used to assess differences 
in the number of apomorphine-induced rotations between groups and the results of 
forelimb use asymmetry tests were analyzed with non-parametric two-way repeated 
measures ANOVA and Bonferroni test. Significant changes in DAT immunolabeling 
between control groups and 6-OHDA lesioned animals were studied by performing a 
non-parametric one-way ANOVA followed by Dunn’s test for the unilateral model and 
Mann Whitney U-test for the bilateral model. 
 
Correlation studies  
 The relationship between striatal dopaminergic activity as revealed by 
PET (week 6), histological and behavioral studies was evaluated by Pearson correlation. 
 
Results 
Figure 3 shows representative PET images at 1 week post-lesion. 11C-DTBZ 
PET binding was reduced in the left striatum of unilaterally-lesioned animals. In the 
bilateral model a reduction of 11C-DTBZ binding was found in the striatum bilaterally. 
No change was observed in control animals. 
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VOI based analysis of PET images 
The changes in 11C-DTBZ SB values in the unilateral and bilateral rat models 
associated with different degrees of 6-OHDA-induced lesion are summarized in Figure 
4.  
 
Figure 4: Time-course analysis of striatal binding (SB) values in the unilateral lesion (A) 
and the bilateral lesion (B) groups. SB data represent mean ± SD and are expressed as the 
percentage of the binding ratio (BR) values of the lesioned side with respect to the intact 
one in the unilateral model (A, sham n=4, lesioned n=22), and as the percentage of the BR 
values of each side with respect to the healthy average in the bilateral model (B, sham n=5, 
lesioned n=13). Parametric two way-ANOVA (A), and Kruskal-Wallis followed by 
Bonferroni correction (B); *p<0.001 sham vs lesion; #p<0.001 lesion vs baseline.  
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(double column fitting image) 
 
In the unilateral model (Figure 4A), the lesion factor (6-OHDA effect) was 
statistically significant (p<0.001), and SB values were reduced at all time-points with 
respect to baseline values (p<0.001). At the first week post-lesion, animals exhibited a 
significant reduction of SB in the left striatum (60% of reduction). At the second week 
post-lesion, mean SB values decreased slightly (65% of reduction) and remained 
unchanged after 3 and 6 weeks post-lesion. The time factor and its interaction with the 
lesion factor were not significant (p=0.746), meaning that there were no changes over 
time for either sham or 6-OHDA lesion groups.  
In the bilateral model (Figure 4B), no statistically significant differences 
between left and right hemisphere were found at any time point (Mann-Whitney U-test; 
p=0.628). Time of evolution after lesion did not reach significance (p=0.089), which 
could be related to large variability within groups. Thus, multiple comparisons 
(Kruskal-Wallis test) between all groups were performed assuming an adjusted p-value 
< 0.001 for significance by Bonferroni correction. At the first week, 6-OHDA bilateral 
lesion was associated with significant reduction (42% left, 49% right) of SB values with 
respect to baseline and sham groups. In the 3rd week after lesion, SB values showed an 
increase and the reduction was not significant in comparison with sham groups, but still 
was in comparison with baseline (24% left, 35% right). No further changes in 11C-
DTBZ SB occurred 6 weeks after the last 6-OHDA administration (28% left and 35% 
right reduction with respect to baseline). 
 
Behavioral evaluations 
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In the unilateral model, sham animals showed no rotational asymmetry while 6-
OHDA-lesioned rats exhibited increased contralateral turning under apomorphine with 
respect to the sham-treated group (p<0.05) (Figure 5A). In the forelimb use test (Figure 
5B), bilaterally lesioned rats showed a significant reduction in the use of forelimbs with 
respect to baseline values (p<0.001) at all time-points; regarding the comparison with 
the sham group the difference was significant at days 11 and 18 after the last 6-OHDA 
injection. Unexpectedly, sham animals also showed reduced values respect to baseline 
(Figure 5B). The catalepsy score of lesioned animals was significantly different from 
baseline values (p<0.001) at all-time points analyzed, except for days 32 and 39 after 
the last injection of 6-OHDA (data not shown). 
 
 
Figure 5. Evaluation of rotational behavior in animals with a unilateral lesion 
(apomorphine test, A, sham n=4, lesioned n=21) and the use of forelimbs (forelimb 
asymmetric use test, B, sham n=5, lesioned n=13) in the bilaterally lesioned rats (expressed 
as mean ± SD). Non-parametric one way-ANOVA (A) and two-way repeated measures 
ANOVA (B) followed by Dunn's and Bonferroni multiple comparison procedures, 
respectively. *p<0.05 sham vs lesion; #p<0.001 lesion vs baseline; &p<0.05 sham vs baseline.  
(double column fitting image) 
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DAT immunoreactivity and striatal denervation 
Optical density analysis in the unilaterally lesioned animals showed that 6-
OHDA induced a significant DAT reduction in the left striatum (by 70%, p<0.001) 
(Figure 6A, B), which was associated to a reduction of the number of TH+ neurons in 
the SN by approximately 60% (Tseng et al., 2005). In the bilateral model, the reduction 
was of 28% (left) and 33% (right) with respect to sham levels (p<0.001) (Figure 6A, C) 
with no difference between striatal sides. This modest reduction is associated with  
65% cell loss (TH+ stereology counting) in the SNpc bilaterally (data not shown; 
Quiroga et al In Preparation). 
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Figure 6. Representative photomicrographs showing dopamine transporter (DAT) 
immunoreactivity in the striatum (A). Semiquantitative optical density analysis of DAT 
immunolabeling in the striatum of unilateral (B) and bilateral (C) lesion models. Data 
represent mean ± SD and are expressed as a percentage respect to the intact side in the 
unilateral model (B, sham n=4, lesioned n=22) and as a percentage compared with sham 
animal values in the bilateral model (C, sham n=5, lesioned n=13). Non-parametric one-
way ANOVA followed by Dunn’s test and Mann Whitney U-test; *p<0.001 sham vs lesion.  
(single column fitting image) 
 
Correlations analysis 
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 There was a highly significant correlation between striatal 11C-DTBZ binding as 
measured in-vivo with microPET (week 6) and DAT striatal immunoreactivity ex-vivo 
values (r = 0.95, p < 0.001, Figure 7A). There was also a significant correlation between 
rotational values and PET studies at the third week after the unilateral lesions (r = -0.91, 
p < 0.001, Figure 7B). On the other hand, forelimb asymmetric use (r = 0.27, p = 0.16) 
and catalepsy-grid (r = -0.28, p = 0.14) scores were not significantly correlated with 
PET changes in the bilateral model. 
 
 
Figure 7. Pearson’s correlation between PET values versus optical density DAT values (A) 
and rotational behavior values (B). There was a highly significant correlation between 11C-
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DTBZ striatal binding (SB) and DAT immunoreactivity labeling (r = 0.95, p < 0.001), and 
also with the rotational test in the unilateral model (r = -0.91, p < 0.001).  
(single column fitting image) 
 
Discussion 
The present study describes the longitudinal evolution of 11C-DTBZ binding in 
the striatum over 6 weeks in rats with a 6-OHDA-induced unilateral lesion in the medial 
forebrain bundle, and bilaterally lesioned rats after injection of the neurotoxin in the 
third ventricle for 7 consecutive days.  
Imaging the nigro-striatal DA system in small animals has become now a 
feasible in-vivo monitoring method to ascertain the degree of dopaminergic depletion. 
Several studies (Sossi et al., 2007; Collantes et al., 2008; Topping et al., 2010) have 
indicated that changes in 11C-DTBZ binding in the striatum can be directly related to 
reduction of VMAT2 density and the loss of dopaminergic terminals, suggesting that 
11C-DTBZ-PET may be a reliable index of nigro-striatal lesion. Indeed, our study shows 
that striatal dopaminergic depletion in two rat models can be ascertained and monitored 
in-vivo by 11C-DTBZ PET with fairly good accuracy. We found an excellent correlation 
between DAT immunohistochemistry labeling in post-mortem tissue and 11C-DTBZ 
PET (Figure 7A), and also with the rotational test in the unilateral model. This contrasts 
somehow with a previous study (Strome et al., 2006) using 6-OHDA-lesioned rats in the 
medial forebrain bundle, which described overestimation in the quantification of 11C-
DTBZ binding in large-sized lesions. These authors suggested that the inability to 
measure large asymmetries by PET in the unilateral model (comparing the lesioned side 
with respect to the intact side, using manually-defined VOIs) could be due to a partial 
volume effect as consequence of limited scanner resolution. Indeed, the limited spatial 
resolution of PET tomographs, particularly when studying small animals, and the 
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presence of low uptake areas make it difficult to delimit VOIs accurately. Consequently, 
the definition of VOIs is probably one of the most critical steps in the quantification 
procedure (Sossi et al., 2007) and introduces great intra- and inter-operator variability. 
In order to minimize such problems, we defined anatomically-standardized VOIs based 
and derived from a T2-weighted MRI (Figure 3) which closely fitted the 11C-DTBZ 
binding pattern in the striatum. These reduced VOIs were placed into the common 
stereotaxic coordinate system (Paxinos and Watson, 2007) and provided a more 
accurate binding measurement than atlas-defined VOIs (Sossi et al., 2007). Moreover, 
we had created an 11C-DTBZ PET template, meant to serve as a reference in spatial 
normalization procedures (Collantes et al., 2009) and quantify PET studies in an 
automated way with our anatomically-standardized VOI map. When images are 
spatially normalized and hence forced to match such a standardized space, those VOIs 
can be directly applied, reducing observer bias in VOI placement. Despite such 
improvements in the methodology, there is still a great difficulty to quantify 11C-DTBZ 
PET in the bilateral 6-OHDA model, mainly as a consequence of the reference used in 
the process. As mentioned above, the reference used in the unilateral model is the intact 
side of the same rat, avoiding the inter-subject variability, whereas the average value of 
healthy rats was used as reference for all bilaterally-lesioned rats. This probably leads to 
larger variability in the comparisons. Indeed, we somewhat unexpectedly found that at 6 
weeks 11C-DTBZ PET values for bilaterally lesion rats were not statistically different 
from the sham-treated group. This contrasts with data for DAT striatal immunoreactivity 
that was significantly reduced in the lesion animals. We need to stress here that the 
differences in BP between lesion and sham groups at 6 weeks post-lesion was close to 
reach significance (p=0.00646), and when assuming an adjusted p-value < 0.001 for 
significance by Bonferroni correction, this was also close to threshold for statistical 
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significance. Thus, we believe that the variability implicit to PET assessment in the 
bilaterally depleted striatum rat mainly explains these findings. Another unexpected 
result was the finding of bilateral sham rats showing a significant reduction of forelimb 
use at several time points compared to their baseline levels. We think that habituation to 
the testing environment leading to reduced activity of the independent limb use upon 
repeated testing at short time intervals may well explain this observation. It could also 
occur that the reduced activity is related with a volume effect of the vehicle injected, but 
we found intact dopaminergic striatal terminals and no evidence of widespread brain 
damage.  
Typically, a severe lesion of the nigro-striatal lesion is inflicted unilaterally in 
the 6-OHDA rat model, which precludes studying compensatory changes during the 
initial stage of dopaminergic loss (Kirik et al., 1998; Rodríguez et al., 2001; 
Sadakierska-Chudy et al., 2010). One original aspect of our study is the longitudinal 
follow-up of the PET changes over several weeks associated with two different 
administration modes of 6-OHDA. This allowed us to establish that the neurotoxin 
causes acute dopaminergic depletion that remained constant along time evolution in the 
unilateral model. In the novel bilateral-lesion rat model used here, which induced a 
slowly progressive lesion over several days of 6-OHDA administration, we found some 
relevant differences with respect to the classic 6-OHDA unilateral model. First, 
although the total 6-OHDA dose used was higher than in unilaterally lesioned animals, 
the bilateral lesions were not as severe as in the unilateral case. Secondly, and 
interestingly, striatal 11C-DTBZ binding increased after the first week and striatal 
denervation (i.e. DAT immunostaining) was roughly half of SNpc cell loss, suggesting 
some degree of dopaminergic striatal recovery perhaps via sprouting of the remaining 
dopaminergic fibers. Some degree of motor improvement is well known to occur in the 
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1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkey model (Elsworth et al 
2000; Mounayar et al., 2007; Blesa et al., 2012) weeks/months after lesioning, but the 
intrinsic mechanisms underlying the recovery remain unraveled. We believe that the 
bilateral rat model may be applied to study compensatory mechanisms associated with 
different levels of nigro-striatal lesion as determined by 11C-DTBZ PET.  
 
Conclusions 
In summary, we found a marked reduction in striatal 11C-DTBZ-PET uptake in 
rats with 6-OHDA lesion, which was graded and proportional to the damage inflicted by 
the toxin. Dopaminergic depletion remained constant along time evolution in unilateral 
lesions whereas the bilateral model showed a modest increase in 11C-DTBZ SB since 
the third week post-lesion. 11C-DTBZ PET appears sensible to detect different degrees 
of changes of nigro-striatal innervation, particularly in the unilateral 6-OHDA model. 
SB values were highly correlated with histological and behavioral (for unilateral lesion) 
manifestations in 6-OHDA lesion rats. Accordingly, 11C-DTBZ binding may be 
considered a useful tool to ascertain and define the degree of nigro-striatal lesion in rat 
models and putative changes occurring spontaneously, i.e. compensatory mechanisms, 
or induced by experimental therapies.  
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